SHELTON -
Event: EF Hutton Annual
Date:
Location:
This year s event will feature key executives from public and private companies to convey their unique stories to an extensive audience which includes institutional investors, high-net worth individuals, corporate clients, and exclusive members of the press. Investors and executives will have the opportunity to interact with each other in a friendly, high-energy environment.
The ultra-broad-spectrum antiviral drug NV-387 could lead to a disruptive change in how we treat viral infections just as penicillin revolutionized how we treat bacterial infections, said
The Company s lead drug, NV-387 has successfully completed Phase 1a/1b human clinical trials in healthy subjects, with no reported adverse events, indicating excellent safety. This clinical trial was sponsored by
The same drug NV-387 has demonstrated strong antiviral activity against viruses from multiple families, including Coronaviruses (SARS-CoV-2, Long COVID, Seasonal coronaviral infections), RSV, Influenza A, as well as a Smallpox/Mpox related mouse virus in stringent, lethal viral infection animal models. In all of these cases, NV-387 led to improvement in survival that substantially exceeded or was at least on par with that from already approved drugs or known antiviral agents.
NV-387 could be the very first single drug that can treat all of the tripledemic viral infections, namely, Coronaviruses, RSV, and Influenza A.
Once the Phase I final report is available, the Company plans to advance NV-387 into Phase II clinical trials for the evaluation of antiviral effect. The Company believes that these clinical trials, if successful, would follow Phase III clinical trials towards regulatory approval of NV-387 to treat various viral infections.
In addition to NV-387, the Company has a broad and deep pipeline of drug candidates against several virus families. The most advanced among these, NV-HHV-1, is the Company s lead drug candidate for the treatment of Shingles rash, HSV-1 cold sores and HSV-2 genital ulcers .
About EF Hutton
EF Hutton is an investment bank headquartered in
EF Hutton continues to be a leader on
About
Our lead drug candidate is NV-387 (drug product NV-CoV-2) for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections. NV-387 has successfully completed a Phase 1a/1b human clinical trial in healthy subjects with no reported adverse events even at the highest and repeated dosages. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for treatment of RSV infection.
Our other advanced candidate is NV-HHV-1 for the treatment of Shingles rash, HSV-1 cold sores and HSV-2 genital ulcers . The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by
The phrases safety , effectiveness and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the
Contact:
Email: info@nanoviricides.com
MJ Clyburn
Email: clyburn@tradigitalir.com
(C) 2024 Electronic News Publishing, source